441results about How to "Short half-life" patented technology

The present invention provides pharmaceutical compositions for controlled release of pharmaceutically active agents, especially those with a high water solubility, high dose, and / or short half-life. In addition, the present application provides methods for preparing and using such pharmaceutical compositions.

A medical device useful for localized delivery of radiation in vivo is provided. The medical device includes a structure including a porous material; and a plurality of discrete particles including a water-insoluble radioactive salt dispersed throughout a substantial portion of the porous material. The water-insoluble radioactive salt is formed by contacting an aqueous radioactive salt solution with a heavy metal water-soluble salt dispersed throughout a substantial portion of the porous material. The heavy metal water-soluble salt can be dispersed in the porous material so that the device can be sterilized and the radioactive material can be loaded in the device in situ, for example, just prior to implantation.

The present invention relates to methods and compositions for increasing the production of high titre stocks of recombinant AAV (rAAV) through regulation of expression of the AAV REP and CAP proteins. The methods and compositions of the invention are based on the observation that the low level expression of the AAV REP protein increases the production of AAV viral capsid protein and efficiency of packaging resulting in production of higher titre recombinant viral stocks. The invention encompasses recombinant AAV vectors that direct the expression of AAV REP and CAP proteins and the use of such vectors for the production of novel stable cell lines capable of generating high titre rAAV vectors. The invention provides methods for regulating the expression of the AAV REP gene at the transcriptional and post-translational level. The methods and compositions of the invention can be used to produce high titre stocks of rAAV which can be used in gene therapy for the purpose of transferring genetic information into appropriate host cells for the management and correction of human diseases including inherited and acquired disorders.

The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl / sufentanil is provided as a water soluble salt (e.g., fentanyl hydrochloride), preferably in a hydrogel formulation, for use in an electrotransport device (10). In accordance with the present invention, a transdermal electrotransport delivered dose of fentanyl / sufentanil is provided which is sufficient to induce analgesia in (e.g., adult) human patients suffering from moderate-to-severe pain associated with major surgical procedures.

The invention is intended for a treatment of severe infections using an injectable drug-delivery system comprising nanoparticles of a biodegradable polymer with incorporated antibacterial drug.

The invention relates to methods and pharmaceutical compositions for inhibiting or preventing preterm birth, inhibiting or delaying cervical ripening, inhibiting myometrial contractility and treating or inhibiting uterine contractility disorders. The methods comprise administering an effective amount of a composition comprising steroid hormones such as soluble progesterone.

A method of conjugating peptides and proteins by means of glycosyltransferase is provided.

Method of conjugating glycoproteins by means of chemical modification is provided as well as new modified glycoproteins.

The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl / sufentanil is provided as a water soluble salt (eg, fentanyl hydrochloride) dispersed in a hydrogel formulation for use in an electrotransport device (10). In accordance with one aspect of the invention, the concentration of fentanyl / sufentanil in the donor reservoir (26) solution is above a predetermined minimum concentration, whereby the transdermal electrotransport flux of fentanyl / sufentanil is maintained independent of the concentration of fentanyl / sufentanil in solution. In accordance with a second aspect of the present invention, the donor reservoir (26) of the electrotransport delivery device (10) is comprised of silver and the donor reservoir (26) contains a predetermined “excess” loading of fentanyl / sufentanil halide to prevent silver ion migration with attendant skin discoloration. In accordance with a third aspect of the present invention, a transdermal electrotransport delivered dose of fentanyl / sufentanil is provided which is sufficient to induce analgesia in (eg, adult) human patients suffering from moderate-to-severe pain associated with major surgical procedures.

The present invention provides compounds and materials that reduce the accumulation of microorganisms a surface, by interfering with the attachment of the organisms to the surface. The compounds and materials are thus useful in preventing the formation of biofilms on surfaces in health-related environments. By preventing the formation of biofilms, the compounds formulated according to the present invention can be used in the fabrication of grafts, implants, medical devices in order to prevent infection thereof. The compounds formulated according to the present invention display an additional anticoagulant property, permitting their use in settings where decrease in blood coagulability is desirable.

Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and / or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.

The present invention relates to Fc-IL-15 hybrids, which may or may not include peptide linkers between the IL-15 and the Fc portion, for methods of treatment of tumors and viral infections. The IL-15 hybrids can be Fc-IL-15 or IL-15-Fc hybrids. The Fc-IL-15 hybrids include variants, including the IL-15 and Fc variants. The hybrids preferably (but not necessarily) include peptide linkers between the IL-15 and the Fc portion. These linkers are preferably composed of a T cell inert sequence, or any non-immunogenic sequence.

To address the issue of degradation by enzymatic reactions to proteins and peptides, polyethylene glycol (PEGylation) of the proteins and peptides has been established. PEGylated proteins and peptides have increased plasma half-lives and reduced immunogenicity. To further improve and extend the plasma half-life of desired protein or peptide therapeutics, a novel branched molecule of PEG possessing three PEGs with a single point of attachment is designed in this invention disclosure.

The present invention relates to methods for treating and / or preventing metabolic diseases comprising the subcutaneous or transdermal administration of a therapeutically effective amount of a certain DPP-4 inhibitor. The invention further relates to a subcutaneous combination of a certain DPP-4 inhibitor and GLP-1 having a short half life, particularly for reducing weight.

The present invention discloses a novel material is represented by the following formula (A), the organic EL device employing the material as blue emitting layer can lower driving voltage, prolong half-lifetime and increase the efficiency.Wherein m represent an integer of 0 to 4, R1 and R2 are identical or different. R1 and R2 are independently selected from the group consisting of a hydrogen atom, alkyl group having 1 to 20 carbon atoms, a substituted or unsubstituted aryl group having 6 to 30 carbon atoms, a substituted or unsubstituted aralkyl group having 6 to 30 carbon atoms. R3 and R4 are identical or different, R3 and R4 are independently selected from the group consisting of hydrogen atom, a halide, a substituted or unsubstituted arylamine, a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms, a substituted or unsubstituted aryl group having 6 to 30 carbon atoms.

The invention relates to protein complexes and fusion proteins including at least two different cytokine molecules. The protein complexes and fusion proteins may further include a targeting moiety such as a region of an immunoglobulin. Methods of using the protein complexes and fusion proteins are also disclosed.

The invention relates to the inhibition of DNA methyltransferase isoforms DNMT1 and DNMT3b2. The invention provides compounds and methods for inhibiting DNMT1 and DNMT3b2.

The invention provides biologically active erythropoietin (EPO) conjugate compositions wherein EPO is covalently conjugated to a non-antigenic hydrophilic polymer covalently linked to an organic molecule that increases the circulating serum half-life of the composition. The invention thus relates to EPO derivatives described by the formula EPO-(X-Y)N where EPO is erythropoietin or its pharmaceutical acceptable derivatives having biological properties of causing bone marrow cells to increase production of reticulocytes and red blood cells, X is PEG or other water soluble polymers, Y is an organic molecule that increases the circulating half-life of the construct more than the PEG alone and N is an integer from 1 to 15. Other molecules may be included between EPO and X and between X and Y to provide the proper functionality for coupling or valency.

The invention belongs to the medicinal preparation field, relates to a cell-penetrating peptide modified nanoparticle, and concretely relates to a nanoparticle delivery system for oral polypeptide and protein medicines, and its preparation method. The medicine delivery system is composed of the nanoparticle, cell-penetrating peptides modified on the surface of the nanoparticle, and the polypeptide protein medicines sealed by the nanoparticle, wherein the average particle size range of the medicine delivery system is 10-500nm. The cell-penetrating peptide modified nanoparticle and glucosaminoglycan having electronegative cell surfaces undergo electric property attraction and then undergo endocytosis, so the cell-penetrating peptide modified nanoparticle and the glucosaminoglycan are integrally taken into cells; and the cell-penetrating peptide modified nanoparticle has an alimentary canal mucous membrane penetrating capability after the cell-penetrating peptide modified nanoparticle is orally taken, and can deliver the polypeptide protein medicines carried by the cell-penetrating peptide modified nanoparticle to the whole body for blood circulation, so the oral biological utilization degree of the medicines are improved. The cell-penetrating peptide modified nanoparticle has the advantages of improvement of the stability of polypeptide and protein medicines in the alimentary canal, reduction of the application amount of cell-penetrating peptides, and reduction of possible toxic side effects caused by the cell-penetrating peptides.

Apparatus for the controllable downhole production of ionizing radiation (12), the apparatus including at least a thermionic emitter (11) which is arranged in a first end portion (7a) of an electrically insulated vacuum container (9), and a lepton target (6) which is arranged in a second end portion (7b) of the electrically insulated vacuum container (9); the thermionic emitter (11) being connected to a series of serially connected negative electrical-potential-increasing elements (141, 142, 143, 144), each of said electrical-potential-increasing elements (141, 142, 143, 144) being arranged to increase an applied direct-current potential (δV0, δV1, δV1+2, . . . , δV1+2+3) by transforming an applied, driving voltage (VAC), and to transmit the increased, negative direct-current potential (δV1, δV1+2, . . . , δV1+2+3+4) and also the driving voltage (VAC) to the next unit in the series of serially connected elements (141, 142, 143, 144,5), and the ionizing radiation (12) exceeding 200 keV with a predominant portion of the spectral distribution within the Compton range.

Methods of detecting and assessing functionally active folate receptors on tumors and treatment associated with those tumors are described. Also described are methods of selecting ovarian and lung cancer patients for therapy with a folate-vinca conjugate by identifying functionally active folate receptors on the tumors of the patient. Also described are methods and compositions for treating folate receptor expressing epithelial tumors with a folate-vinca conjugate in combination with doxorubicin such as pegylated liposomal doxorubicin in which the tumors include ovarian, endometrial or non-small cell lung cancer tumors, including platinum-resistant ovarian tumors and platinum sensitive ovarian tumors. Also described are methods of treating platinum-resistant ovarian cancer using a folate-targeted drug, in the absence or presence of selecting the patient by identifying functionally active folate receptors on the tumors of the patient.

The invention relates to an injectable temperature sensitive gel used for filling and repairing damaged tissues. The gel is characterized in that: medical-grade hyaluronic acid and chitosan are used as gel raw materials; the gel swelling ratio is 2-500; and a temperature sensitive temperature is 32-37 DEG C. The gel provided by the invention has the advantages that the injection temperature sensitive gel has physical and chemical properties of a general gel, also has injectable and temperature sensitive properties and a good fluidity at a room temperature and is easy for injection; the formability in organisms is good and the degradation is slow so that the general gel can not be compared; a cross-linking agent is not used for the gel so that harms of the cross-linking agent to a human body are avoided; a gel system can prolong a persistence time of the gel in a body, and also can continuously stimulate the body to produce reactions so that the tissue in-situ regeneration and repair is promoted and the filling quality is increased; and the gel simultaneously has the advantages of reducing bacterial invansion, anticoagulation and low allergic reaction and the like.

The present invention discloses a new fluorene compound and organic EL device using the compound. The organic EL device employing the new fluorene compound as host material can lower driving voltage, prolong half-lifetime. The fluorene compound can functions as blue emitting host material of a light emitting layer and improve CIE colour purity in blue emitting device. The fluorene compound are represented by the following formula(A):Wherein R1 to R6 are identical or different. R1 to R6 are independently selected from the group consisting of a hydrogen atom, a halide, alkyl group having 1 to 20 carbon atoms, a substituted or unsubstituted aryl group having 6 to 30 carbon atoms, a substituted or unsubstituted aralkyl group having 6 to 30 carbon atoms, a substituted or unsubstituted heteroaryl group having 6 to 30 carbon atoms. R7˜R13 are identical or different R7 to R13 are independently selected from the group consisting of hydrogen atom, halide, alkyl group, aryl group, heteroaryl group. m and n are independently an integer of 0 to 3, X is selected from carbon or nitrogen.

The invention discloses an antibody coupling drug targeting on EGFR, a preparation method thereof and uses thereof. The antibody-conjugated drug targeting EGFR is named LR004-VC-MMAE consisting of anantibody, a cytotoxic drug and a linker, wherein the antibody drug conjugate has a structure represented by the formula I, wherein mAb is an LR004 monoclonal antibody, n=2-8. The novel antibody-conjugated drug LR004-VC-MMAE can not only target EGFR antigen, but also has strong cytotoxicity to tumor cells. Compared with LR004 itself, it did not affect the affinity, endocytosis and targeting of theantibody, and better retained its biological function. Compared to LR004, the antitumor effect of LR004-VC-MMAE antibody-conjugated drug is significantly improved, and the tumor disappeared. Comparedto LR004, LR004-VC-MMAE antibody-conjugated total antibody showed longer half-life, slower clearance rate, lower concentration of free MMAE in plasma, shorter half-life and faster clearance rate, which is conducive to reduce toxicity.

The present invention discloses a novel material is represented by the following formula (A), the organic EL device employing the material as blue emitting layer can lower driving voltage, prolong half-lifetime and increase the efficiency.Wherein m represent an integer of 0 to 4, R1 and R2 are identical or different. R1 and R2 are independently selected from the group consisting of a hydrogen atom, alkyl group having 1 to 20 carbon atoms, a substituted or unsubstituted aryl group having 6 to 30 carbon atoms, a substituted or unsubstituted aralkyl group having 6 to 30 carbon atoms. R3 and R4 are identical or different, R3 and R4 are independently selected from the group consisting of hydrogen atom, a halide, a substituted or unsubstituted arylamine, a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms, a substituted or unsubstituted aryl group having 6 to 30 carbon atoms.

The invention relates to a fusion protein of Exendin-4 tandem polypeptide and human serum albumin, a preparation method and application thereof. The fusion protein of the Exendin-4 tandem polypeptide and the human serum albumin is expressed by a genetic engineering method. The fusion protein shows long-acting controlling blood sugar activity in a body, solves the problem that the half life period of the Exendin-4 tandem polypeptide in the body is short and has the advantage of convenient preparation. The fusion protein can be used for preparing diabetes medicaments and weight-losing products.

A biological measurement apparatus of this invention includes (i) a micro piezoelectric element for vibrating a nerve cell of a subject without coming in contact with the nerve cell, (ii) an electromagnetic wave antenna for receiving an electromagnetic wave generated by the nerve cell vibrated by the micro piezoelectric element, and (iii) a computer for measuring an electric charge of the nerve cell based on the electromagnetic wave received by the electromagnetic wave antenna. Further, this biological measurement apparatus includes an electromagnetic wave antenna for emitting an electromagnetic wave to a nerve cell. This configuration provides an apparatus capable of measuring an electrical activity of a nerve cell in a living organism in real time and three-dimensionally at a spatial resolution of a nerve cell size. Moreover, this configuration provides an apparatus capable of individually giving electrical stimulations to any desired cells in the subject.